`J7667` Metaproterenol comp con

Metaproterenol sulfate, inhalation solution, compounded product, concentrated form, per 10 milligrams

Medicare coverage: Carrier judgment
Status: active (October 2026 file)

Medically Unlikely Edits (effective October 1, 2026)

Practitioner: max 0 units per day (clinical), rationale: Compounded Drug Policy
Outpatient hospital: max 0 units per day (clinical), rationale: Compounded Drug Policy
DME supplier: max 0 units per day (clinical), rationale: Compounded Drug Policy

Medicare pricing for J7667

Physician Fee Schedule (CY 2026, RVU26D)

Status E: excluded from the PFS by regulation.

Payer policies and prior authorization for J7667

Payer coverage policies that name J7667

J7667 appears in 4 coverage policies from Aetna.

Payer	Policy	Role in policy	Reviewed	Document
Aetna	Depemokimab-ulaa (Exdensur) (1098)	listed, no stance (range J7667-J7670)	Aug 10, 2026	payer document
Aetna	Nebulizers (0065)	covered if criteria are met	Mar 18, 2026	payer document
Aetna	Reslizumab (Cinqair) (0907)	listed, no stance (range J7667-J7670)	Aug 10, 2026	payer document
Aetna	Tezepelumab-ekko (Tezspire) (1003)	listed, no stance (range J7667-J7670)	Aug 6, 2026	payer document

Medicaid fee-for-service

Prior authorization required or conditional in IN.

KS: $0.06 (default), effective Jan 1, 2007
VT: $0.00 (outpatient_hospital_opps), effective Feb 1, 2026
WY: $0.00 (outpatient_hospital_apc, Children's Hospitals), effective Apr 1, 2026

From payers' published prior-auth lists, coverage policies and state Medicaid fee schedules, updated Oct 16, 2026. The role is what the policy's own code table or text says about the code. Not a guarantee of coverage or payment; verify with the payer. CPT® is a registered trademark of the American Medical Association.

J7667 Metaproterenol comp con